Viet L. Bui

Viet L. Bui

Auto-generated profile, based on publicly available information

Viet L. Bui

Division of Rheumatology, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2008 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SSStephanie L Sanos
Stephanie L Sanos
VBViet L Bui
Viet L Bui
AMArthur Mortha
Arthur Mortha
KOKarin Oberle
Karin Oberle
CHCharlotte Heners
Charlotte Heners
ADAndreas Diefenbach
Andreas Diefenbach

1 November 2010 in Immunity
Verified
Journal Article
Closed access
CVCedric Vonarbourg
Cedric Vonarbourg
AMArthur Mortha
Arthur Mortha
VBViet L. Bui
Viet L. Bui
PHPedro P. Hernandez
Pedro P. Hernandez
EKElina A. Kiss
Elina A. Kiss
ADAndreas Diefenbach
Andreas Diefenbach

3 April 2021 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
GKGeorge Karpouzas
George Karpouzas
VBViet L Bui
Viet L Bui
NRNicoletta Ronda
Nicoletta Ronda
IHIvana Hollan
Ivana Hollan
SOSarah R Ormseth
Sarah R Ormseth
Introduction: Cardiovascular disease is a leading comorbidity in rheumatoid arthritis. Timely introduction of biologic therapies in a treat-to-target approach has optimized disease-related outcomes and attenuated accrual of comorbidities, including cardiovascular risk. Areas covered: A literature search in MEDLINE (via PubMed) was performed between January 2009 and November 2020. This manuscript explores recent developments in atherosclerotic cardiovascular risk in RA compared with non-RA individuals; it synopsizes differences in vascular function and inflammation, prevalence, burden, vulnerability, and progression of atherosclerotic plaque and their underlying cellular and molecular mechanisms. Finally, it reviews the recent literature on cardioprotective benefits of biologics and draws mechanistic links with inhibition of new plaque formation, stabilization of high-risk lesions and improvement in endothelial function, arterial stiffness, lipid metabolism, and traditional cardiac risk factors. Expert opinion: Increasing evidence points to a solid cardioprotective influence of earlier, longer, and ongoing use of biologic treatments in RA. Nevertheless, the precise mechanistic effects of plaque progression and remodeling, vascular stiffness, endothelial dysfunction, lipid metabolism, and traditional cardiac risk factors are less rigorously characterized.

1 December 2018 in Cell Reports
Verified
Journal Article
Open access
JAJoseph P. Argus
Joseph P. Argus
MWMoses Q. Wilks
Moses Q. Wilks
QZQuan D. Zhou
Quan D. Zhou
WHWei Yuan Hsieh
Wei Yuan Hsieh
EKElvira Khialeeva
Elvira Khialeeva
SBSteven J. Bensinger
Steven J. Bensinger
It is well understood that fatty acids can be synthesized, imported, and modified to meet requisite demands in cells. However, following the movement of fatty acids through the multiplicity of these metabolic steps has remained difficult. To better address this problem, we developed Fatty Acid Source Analysis (FASA), a model that defines the contribution of synthesis, import, and elongation pathways to fatty acid homeostasis in saturated, monounsaturated, and polyunsaturated fatty acid pools. Application of FASA demonstrated that elongation can be a major contributor to cellular fatty acid content and showed that distinct pro-inflammatory stimuli (e.g., Toll-like receptors 2, 3, or 4) specifically reprogram homeostasis of fatty acids by differential utilization of synthetic and elongation pathways in macrophages. In sum, this modeling approach significantly advances our ability to interrogate cellular fatty acid metabolism and provides insight into how cells dynamically reshape their lipidomes in response to metabolic or inflammatory signals.